HIK has been the topic of a number of other reports. Peel Hunt reaffirmed an add rating on shares of Hikma Pharmaceuticals in a research note on Tuesday, September 4th. Citigroup reaffirmed a buy rating and issued a GBX 1,675 ($21.89) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, July 3rd. Numis Securities reiterated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Finally, JPMorgan Chase & Co. reiterated a neutral rating and issued a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 1,346.89 ($17.60).
LON HIK opened at GBX 1,663 ($21.73) on Tuesday. Hikma Pharmaceuticals has a 1-year low of GBX 814.20 ($10.64) and a 1-year high of GBX 2,346 ($30.65).
The firm also recently disclosed a dividend, which was paid on Friday, September 21st. Investors of record on Thursday, August 23rd were issued a $0.12 dividend. This represents a yield of 0.53%. The ex-dividend date was Thursday, August 23rd.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Read More: Find a Trading Strategy That Works
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.